New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
08:06 EDTGENEGenetic Technologies downgraded to Sell from Buy at Ladenburg
Ladenburg downgraded Genetic Technologies two notches to Sell based on concerns it will not be able to secure patent license agreements due to the current patent landscape following the Mayo v Prometheus decision and the July 2012 USPTO decision to reexamination GENE’s ‘179 patent. As a result, the firm sees limited revenue contribution from its pipeline near-term. Price target cut to $1.60 from $7.50.
News For GENE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
05:31 EDTGENEGenetic Technologies appoints Eutillio Buccilli as CEO
Genetic Technologies advised that Eutillio Buccilli has been appointed CEO of the company following the resignation of Alison Mew which was effective 31 December 2014. Buccilli joined the company in June 2014 as the Chief Financial Officer and was appointed to the position of COO and CFO in late 2014.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use